Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis

Fig. 4

CircEAF2 functions as a sponge of miR-BART19-3p in EBV + DLBCL. A CircEAF2-interacting miRNAs profiles were pulled by the biotinylated-circEAF2 probe and compared with oligo probe. B The binding ability of miRNAs was further confirmed by circEAF2 luciferase reporter. The groups transfected wild-type circEAF2 luciferase reporter without miRNA mimics and scramble mimics were used as control group (Ctrl) and negative control group (NC), respectively. C Left panel: Schematic model showed the putative-binding sites for miR-BART19-3p and circEAF2. Right panel: Luciferase assay was performed in HEK293T cells transfected with the wild-type or mutant circEAF2 luciferase reporter and the indicated concentrations of miR-BART19-3p mimics. Results were normalized to a Renilla transfection control. D Enrichment of circEAF2 was pulled down by biotinylated-miR-BART19-3p. E Overexpression of miR-BART19-3p in Farage and SU-DHL-4 cells. Cell proliferation (F), apoptosis assay (G), and epirubicin sensitivity (H) were performed after co-transfection of miR-BART19-3p mimics with circEAF2 plasmid in Farage cells or circEAF2 siRNA in SU-DHL-4 cells. miR-BART19-WT, miR-BART19-3p mimics; miR-BART19-Mut, miR-BART19-3p mutants; Data were shown as the mean ± S.D. of three experiments

Back to article page